logo
What to know about thimerosal, a target of RFK Jr.'s new CDC vaccine advisers

What to know about thimerosal, a target of RFK Jr.'s new CDC vaccine advisers

CNN5 hours ago

A century ago, one of the biggest safety concerns about vaccines involved bacterial contamination. In 1916, four young children died in South Carolina after receiving typhoid vaccine that had been contaminated with Staphylococcus aureus bacteria. Twelve years later, 12 children in Queensland, Australia, died from tainted immunizations against diphtheria.
In the 1930s, vaccine makers began using a preservative called thimerosal to stave off microbial growth in their products. For the next six decades, it didn't receive much notice; ill effects appeared limited to minor local injection-site reactions, according to the US Food and Drug Administration.
That changed in 1999, when US health officials asked pharmaceutical companies to remove thimerosal from vaccines. There was no evidence that it caused harm in the quantities used, but thimerosal contains a form of mercury, and questions had emerged about whether it could cause neurotoxicity when given in childhood vaccinations.
Vaccine makers have removed it from all but a few shots, such as multidose vials of flu vaccine. In the meantime, subsequent studies have confirmed no link between thimerosal in vaccines and neurodevelopmental issues, including autism, and autism rates have continued to rise.
So public health experts were puzzled when the preservative appeared on the agenda for this week's meeting of outside vaccine advisers to the US Centers for Disease Control and Prevention.
'I actually don't know any pediatric practices that even use that multidose influenza vaccine,' said Dr. Sean O'Leary, a pediatrician at Children's Hospital Colorado and former liaison to the CDC's Advisory Committee on Immunization Practices, or ACIP, for the American Academy of Pediatrics.
The group is meeting on Wednesday and Thursday for the first time since US Health and Human Services Secretary Robert F. Kennedy Jr. dismissed the committee's previous 17 members, claiming they had conflicts of interest, and days later installed eight new advisers. Public health experts and lawmakers have called into question the credentials and backgrounds of some of the new panelists, and just before the meeting began, one member withdrew during the financial holdings review, an HHS spokesman said, bringing the panel down to seven.
A presentation 'regarding thimerosal in vaccines' is scheduled for Thursday morning, followed by 'proposed recommendations' specifically about thimerosal in flu vaccines, according to an agenda posted Monday. The meeting is scheduled to conclude with a vote on the latter, a move that could lead to official CDC policy if adopted by agency leadership – or, without a confirmed director in place, by Kennedy.
The last-minute addition of thimerosal to the agenda was a red flag for vaccine experts, who consider the science settled and fear that Kennedy – who led an anti-vaccine group called Children's Health Defense – is seeking to sow doubt about vaccine safety. Another former Children's Health Defense leader, Lyn Redwood, is slated to make a presentation on the topic at the meeting.
Here's how thimerosal became such a hot-button issue.
In 1997, Rep. Frank Pallone, a New Jersey Democrat concerned about mercury pollution in his community's lakes and rivers, attached an amendment to a US Food and Drug Administration reauthorization bill that would require the agency to catalogue intentionally introduced mercury compounds in drugs and food.
That led to a possibly startling discovery: 'As people looked in vaccines, there was the potential that, by six months of age, infants could have received more thimerosal than was listed in several sources of what was considered safe levels of mercury,' said Dr. Walter Orenstein, who was director of the National Immunization Program at the CDC at the time.
But those limits were set for methylmercury, the kind found in some fish, which is known to be toxic. Thimerosal contains ethylmercury, a different compound that's 'intrinsically less stable, and more readily metabolized, than methylmercury,' said Dr. Matthew Rand, an associate professor in the Department of Environmental Medicine at the University of Rochester who studies mercury toxicity.
That means it's cleared from the body more quickly than methylmercury, according to the CDC, 'and is therefore less likely to cause any harm.' The FDA notes that there were no existing guidelines for ethylmercury.
Still, the finding led to a number of emergency meetings among federal health officials and outside groups to determine what should be done, Orenstein recalled.
'While there was no evidence of harm from thimerosal, the general feeling was, 'let's get rid of it, because we don't need it,' ' he said. Moving to single-dose containers alleviated the need for a preservative, although it came at a higher expense for manufacturers.
In 1999, the FDA sent a letter to manufacturers of US vaccines requesting their plans to remove thimerosal, and by 2001, the compound had been removed from or reduced in all vaccines routinely recommended for children under 6 in the US, according to the CDC.
The message from public health agencies, Orenstein said, was 'we're going to make safe vaccines even safer.'
But the die was cast. Vaccines had already been tied to autism in 1998 by British doctor Andrew Wakefield, who published a since-retracted paper that claimed the measles-mumps-rubella vaccine was linked to autism, although not because of thimerosal – the MMR vaccine never contained the preservative.
Still, parents of children with autism were seeking answers.
One of those parents was Redwood, who said that in 1999, she tallied up her son's mercury exposure and found 'at two months of age, he had received 125 times his allowable exposure to mercury based on EPA's guidelines in his weight.'
'That was a real answer for me,' Redwood said in a video posted by Children's Health Defense this month, 'because my son at this time was almost 5 years old, and he had regressed developmentally after his first year of life and was diagnosed with autism.'
Redwood, a nurse practioner, decided to become an advocate, speaking at events and publishing papers about thimerosal and autism.
The uproar over a potential link between thimerosal and autism came as a surprise to Orenstein and colleagues.
'Mercury itself had never been implicated as a major cause of autism,' Orenstein said. 'But this was a major, major concern.'
It led to a number of studies of the issue, including a 2004 assessment by the Institute of Medicine (now known as the National Academy of Medicine) that concluded 'the body of epidemiological evidence favors rejection of a causal relationship between thimerosal-containing vaccines and autism.' It made the same conclusion for MMR vaccines and autism.
A 2010 study by the CDC also found no link. And 'even after thimerosal was removed from almost all childhood vaccines, autism rates continued to increase,' the agency noted, 'which is the opposite of what would be expected if thimerosal caused autism.'
Still, those who continued to push the disproven autism connection included Kennedy, who published a book in 2014 called 'Thimerosal: Let the Science Speak.' Its subtitle calls for the 'immediate removal of mercury – a known neurotoxin – from vaccines.' It rejects the findings of the 2004 Institute of Medicine report and warns that millions of children in the US and around the world 'appear to be at risk of injury from the thimerosal in vaccines.'
Thimerosal is still present in 'a small percentage of flu vaccines, confined to multidose vials,' according to a post from the Vaccine Integrity Project, a group focused on countering vaccine misinformation that was started at the University of Minnesota's Center for Infectious Disease Research and Policy, or CIDRAP.
The group suspects that thimerosal is included on ACIP's agenda this week – with a presentation by Redwood and a vote by the committee – 'to put greater focus on and generate more public discussion about vaccine risk.'
HHS didn't return a request for comment about Redwood's involvement in this week's meeting, and Redwood declined to comment. Her presentation slides, however, were posted ahead of the meeting and continued to claim thimerosal presents safety risks. One slide initially included in the presentation cited a study in animals that appeared not to exist; its apparent lead author told CNN he'd published a study with a similar title, but in a different journal, in different animals, and with dramatically different findings — ones that didn't appear to show a link between autism and thimerosal. The slide presentation was subsequently updated to remove that slide.
CDC staff also posted its own review of the data, citing nearly two dozen studies showing 'the evidence does not support an association between thimerosal-containing vaccines and autism spectrum disorder or other neurodevelopmental disorders.'
During her Senate Health, Education, Labor and Pensions committee confirmation hearing on Wednesday, Dr. Susan Monarez, President Donald Trump's pick to lead the CDC, said, 'I have not seen a causal link between vaccines and autism.'
The decision to remove thimerosal from most vaccines, despite no evidence of harm, had other consequences. At the same time the FDA made its request to vaccine makers, US health authorities advised that babies born to mothers known to be negative for hepatitis B not receive a shot for that virus at birth, but at two months to 6 months of age, as thimerosal was phased out.
But about 10% of hospitals 'suspended use of the hepatitis B vaccine for all newborns, regardless of their level of risk,' wrote Dr. Paul Offit, a vaccine scientist at the Children's Hospital of Philadelphia and a member of the FDA's outside advisory committee on vaccines, in a 2007 perspective piece in the New England Journal of Medicine. 'One three-month-old child born to a Michigan mother infected with hepatitis B virus died of overwhelming infection.'
Orenstein looks back on the decision to remove thimerosal as a hard one.
'The fear would be keeping it in there, doing a study over two or three years and then it showed harm, and lo and behold, for three years, we used this vaccine and this component was harmful,' he said. 'Since we didn't know what the results would be of any of the studies at the time, we thought it better to just get it out of there.
'The autism issue,' he added, 'didn't play any role in the initial decision.'
CNN's Brenda Goodman contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Loneliness Not Tied to Mortality in Older Adult Home Care
Loneliness Not Tied to Mortality in Older Adult Home Care

Medscape

time31 minutes ago

  • Medscape

Loneliness Not Tied to Mortality in Older Adult Home Care

Loneliness is not associated with an increased risk for death among older adults receiving home care in three countries, researchers reported. Bonaventure A. Egbujie, MD, PhD In fact, after adjustment for multiple possible confounders, the survival analysis showed that loneliness was associated with reductions in the 1-year risk for mortality of 18% in Canada, 15% in Finland, and 23% in New Zealand. Nevertheless, 'Loneliness doesn't have to kill you to be a major public health issue,' study author Bonaventure A. Egbujie, MD, PhD, adjunct professor of public health sciences at the University of Waterloo in Waterloo, Ontario, told Medscape Medical News. 'We would like to see policymakers begin to take the issue of loneliness seriously, consider it a quality-of-life issue, and not treat it as a mortality issue, because when you make it a mortality issue, it becomes less likely to be something that you can intervene on.' The findings were published in the Journal of the American Medical Directors Association . Pervasive but Not Deadly The investigators used population-based home care data on 178,611 home care recipients from Canada, 35,073 home care recipients from Finland, and 85,065 home care recipients from New Zealand. Participants were between 65 and over 85 years old, and about 38% were men. Of the Canadian cohort, 15.9% reported being lonely; 20.5% of the Finnish cohort reported being lonely, and 24.2% of the New Zealand cohort reported being lonely. The prevalence of loneliness generally increased with age across the three countries. Loneliness was higher among recipients who had better baseline physical function and worse pain and cognitive performance across the three countries. After adjusting for confounding factors, including age, sex, Alzheimer's disease or dementia, marital status, and living alone or not living alone, the researchers calculated the adjusted hazard ratio (HR) of loneliness and mortality risk as 0.82 in the Canadian cohort, 0.85 in the Finnish cohort, and 0.77 in New Zealand. The findings contrast with existing evidence in the literature suggesting a link between loneliness and death, Egbujie acknowledged. He suggested that the difference may result from the fact that this study was done in a specific group of individuals, whereas other meta-analyses examined the general population. 'One of the reasons we studied the effect of loneliness on older home care recipients is because this group has not been specifically studied,' he said. 'There has been a focus on people in other places, including those in the community, those in hospital, and in nursing homes, but not on this group.' The team also found that the two strongest independent predictors of mortality across the three countries were cancer (Canada, HR, 2.88; Finland, HR, 2.57; and New Zealand, HR, 2.07) and Changes in Health and End-Stage Disease and Symptoms and Signs scores of 3 or more (Canada, HR, 2.66; Finland, HR, 2.61; and New Zealand, HR, 2.65). A limitation of the study was the 1-year follow-up, as health consequences of loneliness may take more time to manifest themselves, the authors noted. In addition, they relied on a single-item measure of loneliness rather than a multi-item summary scale. Egbujie would like to see longer-term studies to better understand whether there is a causal relationship between loneliness and adverse health outcomes and mortality. A shortcoming of the current study, he said, 'is that we don't know the sequence of events. Which appeared first? Was it loneliness that appeared first and led to the health condition, or was it the health condition that appeared first and led to individuals being lonely?' Regardless, 'for clinicians and policymakers, this finding highlights the need to examine home care more carefully,' the authors wrote. 'Loneliness should be addressed as a quality-of-life concern for home care clients in its own right without the need to justify intervention based on mortality risks.' 'Important Public Health Issue' Rachel Savage, PhD, a scientist at Women's College Hospital, an assistant professor at the University of Toronto, Toronto, and a public health researcher who investigates the impact of loneliness on health system use and mortality, commented on the study for Medscape Medical News . She noted that the study is 'methodologically sound, led by a highly respected researcher who is an expert in home care,' and has the key strength of having been replicated across three countries. Savage did not participate in the study. Rachel Savage, PhD She agreed with the authors that the absence of evidence of an increased risk for death from loneliness does not make loneliness unimportant. 'It's not an either/or quality-of-life issue or a mortality risk; it's potentially both,' said Savage. 'We know that loneliness is an important predictor of quality of life and mental health, so even if we do find that it does not increase mortality risk among certain populations, it's still a very important public health issue.' 'There is something unique about the home care population,' she added. 'It's wonderful that these authors have started to build some of the evidence in this group, because, as they state, most of the large meta-analyses that have shown a link between loneliness and an increased risk for premature death are set in the general population.' She noted that females consistently report higher rates of loneliness than males. There could be a few different reasons for this, she said. 'The most obvious one, especially for older adults, is that females on average have a longer life expectancy and so are more likely to experience widowhood and living alone, which are big risk factors for loneliness. Women are also more likely to be caregivers and to have lower incomes, both of which are associated with loneliness. And the last thing is women are more likely to admit their feelings than are men because of social norms.'

Cigna Enhances myCigna Platform With AI Assistant, Personalized Care, Cost Tools
Cigna Enhances myCigna Platform With AI Assistant, Personalized Care, Cost Tools

Yahoo

time42 minutes ago

  • Yahoo

Cigna Enhances myCigna Platform With AI Assistant, Personalized Care, Cost Tools

The Cigna Group (NYSE:CI) is one of billionaire Leon Cooperman's top stock picks with huge upside potential. On June 12, Cigna Healthcare, the health benefits arm of The Cigna Group (NYSE:CI), revealed new digital capabilities designed to enhance the consumer experience during routine health insurance interactions. The myCigna member interface will be used to gradually roll out the new technologies, which include a virtual assistant driven by AI, personalized provider matching, real-time cost tracking, intelligent claim submission, and assistance with plan selection. The AI-powered virtual assistant offers tailored responses to inquiries concerning benefits, claims, and available care options, according to Cigna Healthcare. According to preliminary findings, more than 80% of clients who had access to the virtual assistant found it useful. Additionally, in order to help customers with complicated health needs have their administrative problems resolved more quickly, The Cigna Group (NYSE:CI) is investing in centralized agent teams and increasing access to dedicated My Personal Champion advocates. The Cigna Group (NYSE:CI) specializes in providing insurance and associated services in the United States, such as pharmaceutical benefits, home delivery pharmacy, and specialty pharmacy distribution. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Photo App Could Spot Anemia in Seconds
Photo App Could Spot Anemia in Seconds

Medscape

timean hour ago

  • Medscape

Photo App Could Spot Anemia in Seconds

Artificial intelligence (AI) plays an increasingly prominent role in the workplace, and health researchers are exploring its potential to improve the diagnosis and treatment of diseases. In this context, the company Sanguina Inc., based in the US, has developed an app called Ruby Health, designed to help detect anemia using just a photo of a patient's fingernails. Currently available for Android and iOS devices in the US, the app's effectiveness was detailed in a study published by Sanguina's research team in the journal PNAS . The study and the companion tool grew out of an academic project launched in 2015 by Wilbur Lam, Erika Tyburski, and Rob Mannino. 'The development was rigorous. The idea came from the fact that, for decades, we have known that patients with anemia have paleness in some parts of the body, such as their fingernails, so we thought about the possibility of a noninvasive method, such as an app, to measure this paleness without having to draw blood,' said Lam, a researcher at Emory University School of Medicine in Atlanta, Georgia. Since its launch in 2021, Ruby Health has registered 1.4 million users in the US upload fingernail photos to estimate hemoglobin (Hgb) levels and may manually enter the lab results. Researchers then compare estimated Hgb with blood-test values to gauge accuracy. Among individuals with Hgb between 7 g/dL and 17 g/dL, the mean absolute error was ±0.72 g/dL. Using an Hgb cutoff of 12.5 g/dL to define anemia, the application demonstrated a sensitivity of 89% and a specificity of 93%. For Lam, this tool is promising. 'Based on the values ​​entered, when calibrated, our app works similarly to blood-based methods. With 'homemade' methods, there is always the concern that they do not translate to what is tested in the lab, but we demonstrated the usability of the platform by replicating data in a closed clinical environment and in the real world,' he said. The platform's personal records feature allows for the personalization of treatment tips for patients, and geolocation data helps map cases for the application of public policies and the allocation of treatment resources. However, Ruby Health has limitations: It does not detect very low Hgb levels (< 7 g/dL) and cannot identify the type of anemia the patient has, which is crucial for determining treatment. 'Anemia is not a disease itself but a condition secondary to many illnesses,' said Helena Zerlotti Wolf Grotto, MD, professor of Clinical Pathology at Universidade Estadual de Campinas, Campinas, Brazil, laboratory-hematology consultant, and member of the Brazilian Association of Hematology. 'To determine the cause of anemia, it is necessary to perform tests, evaluate the patient's history and perform a physical examination, since treatment involves comprehensive care,' she said. The gold standard for diagnosing anemia remains the complete blood count, which identifies the type of anemia and its possible causes. 'Screening tests like this app could be useful in remote or resource‐limited areas,' Grotto added. However, in the United States, the app was more widely adopted in areas with higher average incomes, better access to primary care, and a higher proportion of Black residents. In Brazil, Grotto sees limited benefit in urban centers with broad access to laboratory tests, as the public health system already provides robust anemia testing. She is also concerned about accuracy in Black patients, since AI tools often lack adequate training to identify darker skin tones, which could hinder the app's functionality among Brazilians or other mixed-race populations. However, Lam stated that the app's algorithm has been tested on different skin tones and that nails have a lower amount of melanin, which minimizes the variability in skin color from one person to another. Although not 100% accurate, the app can be used to indicate the possibility of a person having anemia in certain cases, according to experts. The developers themselves have stated that it is not suitable for emergency clinical decision-making. 'The market is full of innovations, but we must remain critical before assuming they will solve every problem,' Grotto said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store